Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother
Main Authors: Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2020
Assuntos:
Basic Studies
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144752/
https://ncbi.nlm.nih.gov/pubmed/31899702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000307
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares